ACT Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

ACT Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,000	Closed	-$6K	–	95
2022 Q1	$6K	Hold	5,000	–	–	0.01%	85
2021 Q4	$6K	Hold	5,000	–	–	﹤0.01%	92
2021 Q3	$10K	Hold	5,000	–	–	0.01%	107
2021 Q2	$12K	Buy	+5,000	New	+$12.1K	0.01%	112

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

ACT Capital Management's GNCA Position: Q2 2022 in Review

ACT Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 5,000 shares — an estimated $6K sold.

ACT Capital Management first reported a position in GNCA in Q2 2021 and held it in 4 quarters. The position peaked at $12K in Q2 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

ACT Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
ACT Capital Management sold 5,000 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $6K.
ACT Capital Management first reported a position in Genocea Biosciences, Inc. in Q2 2021 and held it in 4 quarters.
ACT Capital Management's Genocea Biosciences, Inc. position peaked at $12K in Q2 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on ACT Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.